Nicox Ophthalmics, Inc.
Clinical trials sponsored by Nicox Ophthalmics, Inc., explained in plain language.
A subsidiary of Nicox SA, an ophthalmology company developing treatments for eye diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New eye drop aims to beat standard glaucoma treatment
Disease control CompletedThis phase 3 trial tested whether a new eye drop called NCX 470 can lower eye pressure better than the standard drop latanoprost in people with open-angle glaucoma or ocular hypertension. About 696 participants used one drop in each eye every evening for up to 12 months. The stud…
Phase 3 • Sponsor: Nicox Ophthalmics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 15:05 UTC
-
New eye drop study reveals how fluid drains in healthy eyes
Knowledge-focused CompletedThis completed study tested NCX 470 eye drops in 18 healthy adults to see how they change fluid dynamics inside the eye. Participants received either the active drop or a placebo for 8 days. The goal was to measure fluid production, drainage, and pressure. Results will help resea…
Phase 2/3 • Sponsor: Nicox Ophthalmics, Inc. • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:08 UTC